Viking Therapeutics Reported Positive Weight Loss Data

The company released trial results for its dual-agonist drug VK2735, causing shares to surge in value.

Updated on Sept. 23, 2026 in Weight Loss

Isometric editorial illustration of a glass pharmaceutical vial on a clean workbench, representing clinical pharmaceutical trial data. — Viking Therapeutics shares jumped 36 percent after announcing that its experimental drug VK2735 demonstrated significant weight reduction in mid-stage clinical trials. AI Illustration. Upload story photo >

Live Poll

Do you believe the recent developments in weight loss drugs will lead to better health outcomes?

Viking Therapeutics announced positive mid-stage trial results for its obesity drug VK2735, which demonstrated significant body weight reduction. Following the report, the company saw its share price increase by 36 percent.

Why it matters

The trial tested flexible dosing schedules to determine if patients can maintain weight loss success while transitioning away from weekly injections. These findings provide a potential pathway for improving long-term patient adherence to obesity drug therapies.

Participants receiving weekly VK2735 injections achieved 21.7 percent weight loss at 33 weeks, while those transitioning to monthly dosing maintained 85 percent of prior losses. The drug targets both GLP-1 and GIP receptors.

The players

Viking Therapeutics

A clinical-stage biopharmaceutical company based in San Diego that focuses on the development of novel therapies for metabolic and endocrine disorders.

Novo Nordisk

A Danish multinational pharmaceutical company that is a major producer of diabetes and weight management medications.

Roche

A Swiss multinational healthcare company that develops pharmaceuticals and diagnostics.

The details

Trial participants lost between 16 percent and 19 percent of their body weight during the initial 21-week induction period. Those who switched to every-other-week injections after the induction phase maintained 90 percent of their prior weight loss, compared to 61 percent in the placebo group.

September 21, 2026: Novo Nordisk published data for its drug CagriSema.
September 22, 2026: Viking Therapeutics reported trial data and saw its shares surge.
Week 21: Trial participants concluded the initial induction period.
Week 33: Researchers recorded a 21.7 percent weight loss for participants.

Weight Loss
Sept. 21
RNA Therapy Enhanced Fat Loss in Mice Study
Weight Loss
Sept. 23
Wave Life Sciences Launched Obesity Clinical Trial
Biotech
Sept. 22
Vertex And Maze Expanded Kidney Drug Trials

The Big Picture

This development is part of the intense competition within the GLP-1 and GIP dual-agonist drug class. The trial results mark a new entry in the broader landscape of weight-loss research, challenging figures previously established by major pharmaceutical players.

These trial results offer hope for patients who struggle with the convenience of weekly injections, as the study explores the efficacy of monthly or bi-weekly dosing. The findings may eventually lead to more flexible treatment options for those managing obesity.

The takeaway

The study highlights that flexible dosing schedules may be a viable strategy for maintaining significant weight loss results. Patients should consult with healthcare providers regarding the latest clinical developments in metabolic therapy.